Antibiotic activity against naive and induced streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1348-1358

  Vandevelde, Nathalie M ^a   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; POLYSTYRENE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BACTERIUM CULTURE; BIOFILM; BIOMASS; BIOMASS PRODUCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EPITHELIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; NONHUMAN; PLANKTON; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SUPERNATANT;

ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; BIOFILMS; FLUORESCENT DYES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; OXAZINES; STREPTOCOCCUS PNEUMONIAE; XANTHENES;

EID: 84896897964     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01858-13     Document Type: Article

References (77)

1. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002. (Pubitemid 34303762)
2. Moscoso M, Garcia E, Lopez R. 2009. Pneumococcal biofilms. Int. Microbiol. 12:77-85. http://dx.doi.org/10.2436/20.1501.01.84.
3. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318. (Pubitemid 29289651)
4. Hall-Stoodley L, Stoodley P. 2009. Evolving concepts in biofilm infections. Cell. Microbiol. 11:1034-1043. http://dx.doi.org/10.1111/j.1462- 5822.2009.01323.x.
5. Lopez D, Vlamakis H, Kolter R. 2010. Biofilms. Cold Spring Harb. Perspect. Biol. 2:a000398. http://dx.doi.org/10.1101/cshperspect.a000398.
6. Stewart PS. 1996. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob. Agents Chemother. 40:2517-2522. (Pubitemid 26367635)
7. Oggioni MR, Trappetti C, Kadioglu A, Cassone M, Iannelli F, Ricci S, Andrew PW, Pozzi G. 2006. Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol. Microbiol. 61:1196-1210. http://dx.doi.org/ 10.1111/j.1365-2958.2006.05310.x. (Pubitemid 44215421)
8. Simoes M. 2011. Antimicrobial strategies effective against infectious bacterial biofilms. Curr. Med. Chem. 18:2129-2145. http://dx.doi.org/10.2174/ 092986711795656216.
9. Torretta S, Marchisio P, Drago L, Baggi E, De Vecchi E, Garavello W, Nazzari E, Pignataro L, Esposito S. 2012. Nasopharyngeal biofilm-producing otopathogens in children with nonsevere recurrent acute otitis media. Otolaryngol. Head Neck Surg. 146:991-996. http://dx.doi.org/10.1177/ 0194599812438169.
10. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, Forbes M, Greenberg DP, Dice B, Burrows A, Wackym PA, Stoodley P, Post JC, Ehrlich GD, Kerschner JE. 2006. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 296:202-211. http://dx.doi.org/10.1001/jama.296.2.202. (Pubitemid 44050374)
11. Reid SD, Hong W, Dew KE, Winn DR, Pang B, Watt J, Glover DT, Hollingshead SK, Swords WE. 2009. Streptococcus pneumoniae forms surface-attached communities in the middle ear of experimentally infected chinchillas. J. Infect. Dis. 199:786-794. http://dx.doi.org/10.1086/597042.
12. Sanderson AR, Leid JG, Hunsaker D. 2006. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 116: 1121-1126. http://dx.doi.org/10.1097/01.mlg.0000221954.05467.54. (Pubitemid 44317935)
13. Garcia-Castillo M, Morosini MI, Valverde A, Almaraz F, Baquero F, Canton R, del Campo R. 2007. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. J. Antimicrob. Chemother. 59: 301-304. http://dx.doi.org/10.1093/jac/dkl482. (Pubitemid 47072071)
14. Munoz-Elias EJ, Marcano J, Camilli A. 2008. Isolation of Streptococcus pneumoniae biofilm mutants and their characterization during nasopharyngeal colonization. Infect. Immun. 76:5049-5061. http://dx.doi.org/10.1128/IAI.00425- 08.
15. Hall-Stoodley L, Nistico L, Sambanthamoorthy K, Dice B, Nguyen D, Mershon WJ, Johnson C, Hu FZ, Stoodley P, Ehrlich GD, Post JC. 2008. Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol. 8:173. http://dx.doi.org/10.1186/1471-2180-8-173.
16. del Prado G, Ruiz V, Naves P, Rodriguez-Cerrato V, Soriano F, del Carmen PM. 2010. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-Lcysteine, amoxicillin, erythromycin, and levofloxacin. Diagn. Microbiol. Infect. Dis. 67:311-318. http://dx.doi.org/10.1016/j.diagmicrobio.2010.03.016.
17. Lizcano A, Chin T, Sauer K, Tuomanen EI, Orihuela CJ. 2010. Early biofilm formation on microtiter plates is not correlated with the invasive disease potential of Streptococcus pneumoniae. Microb. Pathog. 48:124-130. http://dx.doi.org/10.1016/j.micpath.2010.01.002.
18. Marks LR, Reddinger RM, Hakansson AP. 2012. High levels of genetic recombination during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. mBio 3(5):e00200 -12. http://dx.doi.org/10.1128/mBio. 00200-12.
19. Trappetti C, Ogunniyi AD, Oggioni MR, Paton JC. 2011. Extracellular matrix formation enhances the ability of Streptococcus pneumoniae to cause invasive disease. PLoS One 6:e19844. http://dx.doi.org/10.1371/journal.pone. 0019844.
20. Yadav MK, Chae SW, Song JJ. 2012. In vitro Streptococcus pneumoniae biofilm formation and in vivo middle ear mucosal biofilm in a rat model of acute otitis induced by S. pneumoniae. Clin. Exp. Otorhinolaryngol. 5:139-144. http://dx.doi.org/10.3342/ceo.2012.5.3.139.
21. Drago L, Mattina R, Legnani D, Romano CL, Vianello E, Ricci C, De Vecchi E. 2011. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone. Int. J. Immunopathol. Pharmacol. 24:1027-1035.
22. Tapiainen T, Kujala T, Kaijalainen T, Ikaheimo I, Saukkoriipi A, Renko M, Salo J, Leinonen M, Uhari M. 2010. Biofilm formation by Streptococcus pneumoniae isolates from paediatric patients. APMIS 118:255-260. http://dx.doi.org/10.1111/j.1600-0463.2010.02587.x.
23. Roveta S, Schito AM, Marchese A, Schito GC. 2007. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents 30: 415-421. http://dx.doi.org/10.1016/j.ijantimicag.2007.06.029. (Pubitemid 47498968)
24. Sanchez CJ, Kumar N, Lizcano A, Shivshankar P, Dunning Hotopp JC, Jorgensen JH, Tettelin H, Orihuela CJ. 2011. Streptococcus pneumoniae in biofilms are unable to cause invasive disease due to altered virulence determinant production. PLoS One 6:e28738. http://dx.doi.org/10.1371/journal. pone.0028738.
25. Trappetti C, Kadioglu A, Carter M, Hayre J, Iannelli F, Pozzi G, Andrew PW, Oggioni MR. 2009. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. J. Infect. Dis. 199:1497-1505. http://dx.doi.org/10.1086/598483.
26. Chaney EJ, Nguyen CT, Boppart SA. 2011. Novel method for non-invasive induction of a middle-ear biofilm in the rat. Vaccine 29:1628-1633. http://dx.doi.org/10.1016/j.vaccine.2010.12.076.
27. Cogan NG, Keener JP. 2004. The role of the biofilm matrix in structural development. Math. Med. Biol. 21:147-166. http://dx.doi.org/10.1093/imammb/21.2. 147. (Pubitemid 38867857)
28. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108. http://dx.doi.org/10.1038/nrmicro821. (Pubitemid 39490064)
29. Dai L, Yang L, Parsons C, Findlay VJ, Molin S, Qin Z. 2012. Staphylococcus epidermidis recovered from indwelling catheters exhibit enhanced biofilm dispersal and "self-renewal" through downregulation of agr. BMC Microbiol. 12:102. http://dx.doi.org/10.1186/1471-2180-12-102.
30. Woo JK, Webb JS, Kirov SM, Kjelleberg S, Rice SA. 2012. Biofilm dispersal cells of a cystic fibrosis Pseudomonas aeruginosa isolate exhibit variability in functional traits likely to contribute to persistent infection. FEMS Immunol. Med. Microbiol. 66:251-264. http://dx.doi.org/10.1111/j.1574-695X.2012.01006.x.
31. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238. http://dx.doi.org/10.1128/ AAC.01123-09.
32. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson BD, Fernandes P. 2013. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob. Agents Chemother. 57:2526-2534. http://dx.doi.org/10. 1128/AAC.00197-13.
33. Jorgensen JH, Doern GV, Ferraro MJ, Knapp CC, Swenson JM, Washington JA. 1992. Multicenter evaluation of the use of Haemophilus test medium for broth microdilution antimicrobial susceptibility testing of Streptococcus pneumoniae and development of quality control limits. J. Clin. Microbiol. 30:961-966.
34. Avery OT, Macleod CM, McCarty M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type III. J. Exp. Med. 79:137-158. http://dx.doi.org/10.1084/jem.79.2.137.
35. Hoskins J, Alborn WE, Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR, Jr, Skatrud PL, Glass JI. 2001. Genome of the bacterium Streptococcus pneumoniae strain R6. J. Bacteriol. 183:5709-5717. http://dx.doi.org/10.1128/JB.183.19.5709-5717.2001. (Pubitemid 32898618)
36. Iannelli F, Pearce BJ, Pozzi G. 1999. The type 2 capsule locus of Streptococcus pneumoniae. J. Bacteriol. 181:2652-2654. (Pubitemid 29181596)
37. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. 22nd informational supplement (MS100-S22). Clinical and Laboratory Standards Institute, Wayne, PA.
38. Christensen GD, Simpson WA, Bisno AL, Beachey EH. 1982. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect. Immun. 37:318-326. (Pubitemid 12095221)
39. Tote K, Vanden Berghe D, Maes L, Cos P. 2008. A new colorimetric microtitre model for the detection of Staphylococcus aureus biofilms. Lett. Appl. Microbiol. 46:249-254. http://dx.doi.org/10.1111/j.1472-765X.2007.02298.x.
40. Tote K, Horemans T, Vanden Berghe D, Maes L, Cos P. 2010. Inhibitory effect of biocides on the viable masses and matrices of Staphylococcus aureus and Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol. 76:3135-3142. http://dx.doi.org/10.1128/AEM.02095-09.
41. Gawande PV, LoVetri K, Yakandawala N, Romeo T, Zhanel GG, Cvitkovitch DG, Madhyastha S. 2008. Antibiofilm activity of sodium bicarbonate, sodium metaperiodate and SDS combination against dental unit waterline-associated bacteria and yeast. J. Appl. Microbiol. 105:986-992. http://dx.doi.org/10.1111/ j.1365-2672.2008.03823.x.
42. Natto MJ, Savioli F, Quashie NB, Dardonville C, Rodenko B, de Koning HP. 2012. Validation of novel fluorescence assays for the routine screening of drug susceptibilities of Trichomonas vaginalis. J. Antimicrob. Chemother. 67:933-943. http://dx.doi.org/10.1093/jac/dkr572.
43. Piwonski HM, Goomanovsky M, Bensimon D, Horovitz A, Haran G. 2012. Allosteric inhibition of individual enzyme molecules trapped in lipid vesicles. Proc. Natl. Acad. Sci. U. S. A. 109:E1437-E1443. http://dx.doi.org/10.1073/pnas. 1116670109.
44. Moscoso M, Garcia E, Lopez R. 2006. Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J. Bacteriol. 188:7785-7795. http://dx.doi.org/10.1128/JB. 00673-06. (Pubitemid 44764515)
45. Kurola P, Tapiainen T, Sevander J, Kaijalainen T, Leinonen M, Uhari M, Saukkoriipi A. 2011. Effect of xylitol and other carbon sources on Streptococcus pneumoniae biofilm formation and gene expression in vitro. APMIS 119:135-142. http://dx.doi.org/10.1111/j.1600-0463.2010.02703.x.
46. Trappetti C, Gualdi L, Di Meola L, Jain P, Korir CC, Edmonds P, Iannelli F, Ricci S, Pozzi G, Oggioni MR. 2011. The impact of the competence quorum sensing system on Streptococcus pneumoniae biofilms varies depending on the experimental model.BMCMicrobiol. 11:75. http://dx.doi.org/10.1186/1471-2180-11- 75.
47. Bauer J, Siala W, Tulkens PM, Van Bambeke F. 2013. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 57:2726-2737. http://dx.doi.org/10.1128/AAC.00181- 13.
48. O'Brien J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267:5421-5426. http://dx.doi.org/10.1046/j.1432- 1327.2000.01606.x.
49. Allegrucci M, Hu FZ, Shen K, Hayes J, Ehrlich GD, Post JC, Sauer K. 2006. Phenotypic characterization of Streptococcus pneumoniae biofilm development. J. Bacteriol. 188:2325-2335. http://dx.doi.org/10.1128/JB.188.7.2325-2335.2006.
50. Marks LR, Parameswaran GI, Hakansson AP. 2012. Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo. Infect. Immun. 80:2744-2760. http://dx.doi.org/10.1128/ IAI.00488-12.
51. Scherba G, Weigel RM, O'Brien WD, Jr. 1991. Quantitative assessment of the germicidal efficacy of ultrasonic energy. Appl. Environ. Microbiol. 57:2079-2084.
52. Ceri H, Olson ME, Morck DW. 2004. Methods for biofilm study and assays for biofilm susceptibility and target recognition: approaches to deal with the biofilm mode of life, p 53-85. In Jordan R, Willams D, Charaf U (ed), Advances in biofilm science and engineering. Cytergy Publishing, Bozeman, MT.
53. Otto M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228.
54. Hammerschmidt S, Wolff S, Hocke A, Rosseau S, Muller E, Rohde M. 2005. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect. Immun. 73:4653-4667. http://dx.doi.org/10. 1128/IAI.73.8.4653-4667.2005. (Pubitemid 41105621)
55. Boles BR, Horswill AR. 2011. Staphylococcal biofilm disassembly. Trends Microbiol. 19:449-455. http://dx.doi.org/10.1016/j.tim.2011.06.004.
56. Ross EM, Kenakin T. 2001. Pharmacodynamics: mechanism of drug action and the relationship between drug concentration and effect, p 31-43. In Hardman J, Limbird LE (ed), Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill Medical Publishing Division, New York, NY.
57. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851. http://dx.doi.org/10.1128/AAC.50.3.841-851.2006. (Pubitemid 43327786)
58. Buyck JM, Tulkens PM, Van Bambeke F. 2013. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob. Agents Chemother. 57:2310-2318. http://dx.doi.org/10.1128/AAC.02609-12.
59. Moskowitz SM, Foster JM, Emerson J, Burns JL. 2004. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42:1915-1922. http://dx.doi.org/10.1128/JCM.42.5.1915-1922.2004. (Pubitemid 38637802)
60. Brook I, Hausfeld JN. 2006. In vitro effects of penicillin and telithromycin on the expression of Streptococcus pneumoniae capsule. J. Antimicrob. Chemother. 58:678-679. http://dx.doi.org/10.1093/jac/dkl261. (Pubitemid 44288139)
61. Fernebro J, Andersson I, Sublett J, Morfeldt E, Novak R, Tuomanen E, Normark S, Normark BH. 2004. Capsular expression in Streptococcus pneumoniae negatively affects spontaneous and antibiotic-induced lysis and contributes to antibiotic tolerance. J. Infect. Dis. 189:328-338. http://dx.doi.org/10.1086/ 380564. (Pubitemid 38147258)
62. Gillis RJ, Iglewski BH. 2004. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J. Clin. Microbiol. 42:5842-5845. http://dx.doi.org/10.1128/ JCM.42.12.5842-5845.2004. (Pubitemid 39664375)
63. Fujimura S, Sato T, Mikami T, Kikuchi T, Gomi K, Watanabe A. 2008. Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. Int. J. Antimicrob. Agents 32:481-484. http://dx.doi.org/10.1016/j.ijantimicag.2008.06. 030.
64. Sanchez CJ, Shivshankar P, Stol K, Trakhtenbroit S, Sullam PM, Sauer K, Hermans PW, Orihuela CJ. 2010. The pneumococcal serine-rich repeat protein is an intra-species bacterial adhesin that promotes bacterial aggregation in vivo and in biofilms. PLoS Pathog. 6:e1001044. http://dx.doi.org/10.1371/journal.ppat. 1001044.
65. Vidal JE, Ludewick HP, Kunkel RM, Zahner D, Klugman KP. 2011. The LuxS-dependent quorum-sensing system regulates early biofilm formation by Streptococcus pneumoniae strain D39. Infect. Immun. 79:4050-4060. http://dx.doi.org/10.1128/IAI.05186-11.
66. Jenkins SG, Farrell DJ. 2009. Increase in pneumococcus macrolide resistance, United States. Emerg. Infect. Dis. 15:1260-1264. http://dx.doi.org/10.3201/eid1508.081187.
67. Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. 2007. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 67:2355-2382. http://dx.doi.org/10.2165/00003495- 200767160-00005. (Pubitemid 350071047)
68. Low DE. 2013. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (Should macrolide monotherapy be used for mild pneumonia?) Infect. Dis. Clin. North Am. 27:87-97. http://dx.doi.org/10.1016/j.idc.2012.11.013.
69. Credito K, Kosowska-Shick K, McGhee P, Pankuch GA, Appelbaum PC. 2010. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Antimicrob. Agents Chemother. 54:673-677. http://dx.doi.org/10.1128/AAC.01353-09.
70. Simoens S, Verhaegen J, van Bleyenbergh P, Peetermans WE, Decramer M. 2011. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones. Antimicrob. Agents Chemother. 55: 3051-3053. http://dx.doi.org/10.1128/AAC.00019-11.
71. Patel SN, McGeer A, Melano R, Tyrrell GJ, Green K, Pillai DR, Low DE. 2011. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob. Agents Chemother. 55:3703-3708. http://dx.doi.org /10.1128/AAC.00237-11.
72. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN. 2010. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int. J. Antimicrob. Agents 35:537-543. http://dx.doi.org/10.1016/j. ijantimicag.2010.01.026.
73. Cole PJ, Roberts DE, Davies SF, Knight RK. 1983. A simple oral antimicrobial regimen effective in severe chronic bronchial suppuration associated with culturable Haemophilus influenzae. J. Antimicrob. Chemother. 11:109-113. http://dx.doi.org/10.1093/jac/11.2.109. (Pubitemid 13185532)
74. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. 1996. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40: 2375-2379. (Pubitemid 26328049)
75. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P. 2012. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob. Agents Chemother. 56:5076-5081. http://dx.doi.org/10.1128/AAC.00766-12.
76. Conte JE, Jr, Golden JA, McIver M, Little E, Zurlinden E. 2007. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int. J. Antimicrob. Agents 30:422-427. http://dx.doi.org/10.1016/j.ijantimicag.2007.05.023. (Pubitemid 47500200)
77. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44:835-838. http://dx.doi.org/10.1093/jac/44.6.835.